01—Abstract
Summary
Summary of the 8-K filed September 3, 2026. Cited figures are marked; the original filing is the authoritative source.
Teva Pharmaceutical Industries Limited filed this Form 8-K to recast its historical segment information, as set out in its Annual Report on Form 10-K for the year ended December 31, 2025, filed February 3, 2026.
The change moves Anda, the company's U.S. distribution business, out of the United States segment and into Other Activities, effective January 1, 2026. Management says this lets the United States segment manage its entire product portfolio in the region while strengthening focus on its biopharmaceutical business, growth engines and innovation. The recast was applied to the quarter ended March 31, 2026.
The filing states that it is not an amendment or restatement. Consolidated balance sheets, statements of income (loss), comprehensive income (loss), changes in equity and cash flows are unchanged. The filing also says it does not update the original report for later events, so it should be read together with the original 10-K and the Forms 10-Q for the quarters ended March 31, 2026 and June 30, 2026.
According to the recast Item 7 discussion, the United States segment generated 2025 revenues of $7.69 billiona and segment profit of $3.31 billion, with prior-period amounts recast. Total 2025 revenues were $17,258 million, up 4% in U.S. dollars. Investors should treat the change as a presentation update that affects segment comparability rather than a change in reported consolidated results.
02—Key points
Key Highlights
- Anda, Teva's U.S. distribution business, is no longer reported in the United States segment and is now included in Other Activities, effective January 1, 2026.
- The change is described as aligned with the Pivot to Growth strategy and intended to focus the United States segment on its biopharmaceutical business, growth engines and innovation.
- The recast was applied to segment reporting effective for the quarter ended March 31, 2026, and is reflected retrospectively in Items 1, 7 and 8 of the 2025 Form 10-K.
- The filing states that consolidated balance sheets, income statements, comprehensive income, equity and cash flow statements are unchanged.
- Recast 2025 United States segment revenues are stated at $7.69 billion, with segment profit of $3.31 billion; total 2025 revenues were $17,258 million.
- The filing is not an amendment or restatement and does not update the original 10-K for subsequent events.
- Consent of Kesselman & Kesselman, a member of PricewaterhouseCoopers International Ltd., is included as Exhibit 23.1.
03—Questions
Frequently Asked Questions
Does this filing change Teva's reported consolidated financial results for 2025?
No. The filing states there are no changes to the previously reported consolidated balance sheets, statements of income (loss), comprehensive income (loss), changes in equity or cash flows. The change affects only segment reporting.
Why is Anda moving out of the United States segment?
The filing says the move aligns with Teva's Pivot to Growth strategy. It allows the United States segment to manage its entire product portfolio in the region and strengthens focus on its biopharmaceutical business, growth engines and innovation.
When did the segment change take effect?
Anda has been reported in Other Activities since January 1, 2026. The company aligned its internal financial and segment reporting, and its reporting units, effective for the quarter ended March 31, 2026.
How should investors use this filing alongside Teva's other reports?
The filing states that it should be read together with the original 2025 Form 10-K filed February 3, 2026, and the Forms 10-Q for the quarters ended March 31, 2026 and June 30, 2026. It does not update the original report for later events.
04—Continue